comprehensive -WSS

comprehensive

author：comprehensive 2025-10-06 13:13:37 Page View：534

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pharma showers House GOP doctor with campaign cash
Next article： Walensky prepares to leave CDC — and Congress — behind

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

UK homeowners get some respite as inflation falls by more than anticipated to a 15

SadieJames,right,andJonTaylor,adebtmanageratthecharityChristiansAgainstPoverty,readthedocumentsfroma

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

HONOLULU--TheFederalAviationAdministrationsaidFridaythatitissettingupanewprocessforairtouroperatorsi